Replimune Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Replimune Stock Summary

Replimune competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Replimune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 206 people.

Replimune Key Financial Ratios

Replimune Key Balance Sheet Accounts

Replimune Key Income Statement Accounts

Replimune Key Cash Accounts

Replimune Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Replimune's current stock value. Our valuation model uses many indicators to compare Replimune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Replimune competition to find correlations between indicators driving Replimune's intrinsic value. More Info.Replimune Group is rated second in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Replimune's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Replimune by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Replimune Group Systematic Risk

Today, most investors in Replimune Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Replimune's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Replimune growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Replimune help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Replimune Group. We use our internally-developed statistical techniques to arrive at the intrinsic value of Replimune Group based on widely used predictive technical indicators. In general, we focus on analyzing Replimune Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Replimune's daily price indicators and compare them against related drivers.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.